Trend Report

Future Proofing Against Forever Chemicals: PFAS Ban & Parenteral Packaging

How the proposed EU PFAS ban could reshape parenteral packaging — and why understanding the difference between monomeric and polymeric PFAS is essential for pharmaceutical manufacturers planning ahead.

Status Published

Format Trend Report

Language English

Access Registration Required

Read the Report

Resource Overview

About this Trend Report

The European Chemicals Agency's proposed restriction on per- and polyfluoroalkyl substances (PFAS) — submitted by five EU member states in January 2023 — has created significant uncertainty for pharmaceutical manufacturers that rely on fluoropolymer coatings, PTFE, and PVDF across their parenteral packaging supply chains. This 2025 report by Datwyler cuts through the regulatory complexity by drawing a critical scientific distinction between monomeric PFAS such as PFOA and PFOS — which are bio-accumulative, mobile, and toxic — and polymeric PFAS (fluoropolymers), which are non-toxic, non-bioavailable, non-water soluble, and non-mobile.

The report explains why a blanket ban on all PFAS would be disproportionate: according to EFPIA, such a ban would put more than 600 WHO Essential Medicines at risk and affect at least 47,677 global marketing authorizations. The paper then turns to Datwyler's specific coating portfolio — OmniFlex® spray-coated stoppers, NeoFlex™ plungers, and UltraShield™ film coating — and assesses each technology's regulatory risk profile. OmniFlex and NeoFlex already use non-fluorosurfactant (NFS)-grade fluoropolymers and have been analytically confirmed free of monomeric PFAS, making them the recommended near-term choice for pharmaceutical companies seeking future-proof coated components. The report calls for pharmaceutical manufacturers to engage proactively with their packaging suppliers now, before application-specific ECHA guidance is issued.

ECHA's proposed PFAS ban fails to differentiate between harmful monomeric PFAS and safe polymeric fluoropolymers — a distinction that is scientifically critical, since fluoropolymers used in parenteral packaging coatings are non-toxic, non-bioavailable, and non-mobile, and represent the best-available technology for protecting biologics from extractables and leachables contamination.
A blanket PFAS ban could affect over 70% of Europe's critical medicines and require stability study restarts and regulatory resubmissions across virtually every drug product on the market — making early scenario planning and supplier dialogue a strategic imperative for pharmaceutical packaging teams.
Datwyler's OmniFlex® and NeoFlex™ spray coating technologies, which use non-fluorosurfactant (NFS) grade fluoropolymers free of monomeric PFAS, represent the most regulatorily defensible coated component option currently available.

Future Proofing Against Forever Chemicals: PFAS Ban & Parenteral Packaging

About this Trend Report

Download the Trend Report

More Coating Technology Resources

NeoFlex™: Discover the Future of Sensitive Drug Delivery with Innovative Coated Plungers

Flip caps engineered to combine safety and sustainability

Coated Sealing Solutions for Sensitive Drugs

Stay informed on Datwyler Healthcare technical resources